Search - tctmd.com

Displaying 1 - 20 of 120

Sort: Relevancy | Date

Presentation TCT 2016

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David Hildick-Smith

November 02, 2016

Presentation TCT 2016

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Presenter: Martin B. Leon, Louis A. Cannon, David R. Holmes Jr.

November 02, 2016

Presentation TCT 2016

Global Hearts Action Plan for 2017

Presenter: Jack C. Lewin, Hugh J. Linnehan, Mpiko Ntsekhe

November 01, 2016

Presentation TCT 2016

Needs Assessment for Cath Lab Improvement and Support

Presenter: Jack C. Lewin, Hugh J. Linnehan, Graham A. Cassel

November 01, 2016

Presentation TCT 2016

PASCAR: Global Hearts Sub-Saharan Africa PCI Capacity Survey Results

Presenter: Jack C. Lewin, Hugh J. Linnehan, Habib Gamra

November 01, 2016

Presentation TCT 2016

Update on Epidemiology, Prevention, Screening, and Control

Presenter: Habib Gamra, Ahmed Suliman, Bernard J. Gersh

November 01, 2016

News Industry News TCT 2016

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

November 01, 2016

News Conference News TCT 2016

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Yael L. Maxwell

November 01, 2016

Presentation TCT 2016

Optimizing Fluid Administration for Contrast Nephropathy Prevention

Presenter: Somjot S. Brar, Richard Solomon

November 01, 2016

Presentation TCT 2016

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Presenter: Bernard J. Gersh, Felix Mahfoud, Ori Ben-Yehuda

November 01, 2016

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

Presentation TCT 2016

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

Presenter: Bernard J. Gersh, Felix Mahfoud

November 01, 2016

Presentation TCT 2016

TCT 387: Sirolimus-Coated Balloons for the Prevention of Vascular Restenosis in Small Vessel Disease: Insights From the Nanoluté Registry

Presenter: Germano Di Sciascio, Bruno Scheller

November 01, 2016

Presentation TCT 2016

Twelve-Month Safety and Efficacy of CGuard Micro-Net-Covered Embolic Prevention System: Routine Use to Perform Carotid Revascularization in Symptomatic and Increased Stroke Risk Asymptomatic Patients: The PARADIGM All-Comer Prospective Study

Presenter: Robert M. Bersin, John R. Laird Jr., Piotr Musialek

November 01, 2016

Presentation TCT 2016

Update on Radial Artery Occlusion: Incidence, Presentation, Prevention, and Treatment

Presenter: Francesco Burzotta, Sunil V. Rao, Samir B. Pancholy

October 30, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Presentation TCT 2015

Neurological Complications of TEVAR: Prevention and Management

Presenter: Wilson Y. Szeto, Rodney White, Michael D. Dake

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Presenter: Eric R. Bates, Neal S. Kleiman, Ori Ben-Yehuda

October 15, 2015

Advertisement

AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation

Global Hearts Action Plan for 2017

Needs Assessment for Cath Lab Improvement and Support

PASCAR: Global Hearts Sub-Saharan Africa PCI Capacity Survey Results

Update on Epidemiology, Prevention, Screening, and Control

Long-Term Study Results Show that PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke

Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention

Optimizing Fluid Administration for Contrast Nephropathy Prevention

Hot Topic #3: Anti-ischemic Therapy: Beta Blockers, ACE Inhibitors, and Ranolazine - Are They Effective?

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Hot Topic #1: Implications of the SPRINT Trial on the Target for Blood Pressure Control

TCT 387: Sirolimus-Coated Balloons for the Prevention of Vascular Restenosis in Small Vessel Disease: Insights From the Nanoluté Registry

Twelve-Month Safety and Efficacy of CGuard Micro-Net-Covered Embolic Prevention System: Routine Use to Perform Carotid Revascularization in Symptomatic and Increased Stroke Risk Asymptomatic Patients: The PARADIGM All-Comer Prospective Study

Update on Radial Artery Occlusion: Incidence, Presentation, Prevention, and Treatment

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Neurological Complications of TEVAR: Prevention and Management

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content